ArticleMolecular neurobiology2026
Therapeutic Effects of Spent Ground Coffee Oil on Nociception, Anxiety- and Depression-Like Behaviors, and Inflammatory Mechanisms in a CFA-Induced Intraplantar Inflammation Model in Mice.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spent ground coffee oil (SGCO), rich in antioxidants and bioactive compounds, exhibits anti-inflammatory and analgesic properties and therefore warrants investigation in inflammatory pain models. This study aimed to investigate the topical effects of SGCO on hyperalgesia, emotional behavior, and inflammation-related mechanisms in a Complete Freund's Adjuvant (CFA)-induced inflammation model. SGCO was extracted from spent coffee grounds via non-thermal plasma (NTP) and incorporated into a transdermal vehicle at 10%, 20%, and 30% (w/w). Female Balb/c mice (2 months old, n = 8/group) received daily topical applications of SGCO for 14 days after CFA-induced inflammation. Mechanical and cold nociception and paw edema were assessed. The concentration with the strongest antihyperalgesic effect (20%) was used in further experiments assessing mechanical conflict avoidance, anxiety- and depression-like behaviors, cytokine and oxidative parameters (paw, spinal cord, hippocampus, and prefrontal cortex), and inflammatory pathways in paw tissue. SGCO at 10%, 20%, and 30% produced significant antihyperalgesic effects without affecting paw edema, with 20% providing a sustained effect for 11 days. SGCO 20% was associated with reduced anxiety-like behavior, improved hedonic-like behavior without altering locomotion, and reduced pro-inflammatory cytokines (interleukin-1β and tumor necrosis factor), myeloperoxidase activity, phospho-Akt1/2/3, and NLRP3 in paw tissue. Additionally, it decreased protein carbonyl levels while increasing sulfhydryl group levels in the prefrontal cortex and hippocampus. These findings indicate that SGCO modulates inflammatory and oxidative pathways associated with CFA-induced inflammation and produces measurable effects on nociceptive and behavioral outcomes. Although the magnitude of the effects was generally modest, SGCO obtained via NTP technology may represent a low-cost and environmentally sustainable source of bioactive compounds for further preclinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.